Literature DB >> 8630376

Mutations in the Wilms' tumor gene WT1 in leukemias.

L King-Underwood1, J Renshaw, K Pritchard-Jones.   

Abstract

The tissue-specific Wilms' tumor gene WT1 is expressed in a range of acute leukemias and hematopoietic cell lines. Using single-strand conformational polymorphism analysis, we have found mutations in the WT1 gene in 4 of 36 acute leukemias. WT1 mutations are found in 15% of cases of acute myeloid leukemia, in which they are associated with a poor response to chemotherapy. The mutations comprise small insertions in exons 1 and 7 and a nonsense mutation in exon 9. All are predicted to produce a truncated WT1 protein with absence or disruption of the zinc finger region. These are the first mutations in the WT1 gene to be described in sporadic leukemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 2.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.

Authors:  Subarna Sinha; Daniel Thomas; Linda Yu; Andrew J Gentles; Namyoung Jung; M Ryan Corces-Zimmerman; Steven M Chan; Andreas Reinisch; Andrew P Feinberg; David L Dill; Ravindra Majeti
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

4.  WT1 mutations in T-ALL.

Authors:  Valeria Tosello; Marc R Mansour; Kelly Barnes; Maddalena Paganin; Maria Luisa Sulis; Sarah Jenkinson; Christopher G Allen; Rosemary E Gale; David C Linch; Teresa Palomero; Pedro Real; Vundavalli Murty; Xiaopan Yao; Susan M Richards; Anthony Goldstone; Jacob Rowe; Giuseppe Basso; Peter H Wiernik; Elisabeth Paietta; Rob Pieters; Martin Horstmann; Jules P P Meijerink; Adolfo A Ferrando
Journal:  Blood       Date:  2009-06-03       Impact factor: 22.113

5.  Δ-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Roy G Rich; Michael J Hafez; Shuko Harada; Kathleen M Murphy; James R Eshleman; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

6.  Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

Authors:  Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

7.  Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis.

Authors:  Elodie Pronier; Robert L Bowman; Jihae Ahn; Jacob Glass; Cyriac Kandoth; Tiffany R Merlinsky; Justin T Whitfield; Benjamin H Durham; Antoine Gruet; Amritha Varshini Hanasoge Somasundara; Raajit Rampal; Ari Melnick; Richard P Koche; Barry S Taylor; Ross L Levine
Journal:  Blood       Date:  2018-07-31       Impact factor: 22.113

8.  The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.

Authors:  L W Ellisen; N Carlesso; T Cheng; D T Scadden; D A Haber
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

Review 9.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

10.  Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands.

Authors:  H Nagel; R Laskawi; H Eiffert; T Schlott
Journal:  Mol Pathol       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.